Altasciences selezionata da Steel Therapeutics per supportare il lancio di uno studio tossicologico fondamentale su Fizurex™

Written by Emily J. Thompson, Senior Investment Analyst

Source: Businesswire

Updated: Aug 21 2025

0mins

Source: Businesswire

Partnership Announcement: Altasciences has been selected by Steel Therapeutics, Inc. to conduct a pivotal toxicology study on Fizurex™, a new topical treatment for anal fissures.
Study Compliance: The study is being conducted in accordance with Good Laboratory Practice (GLP) at Altasciences' preclinical facility in Columbia, MO.
Regulatory Milestone: This study represents a significant milestone in Steel's regulatory development as the company prepares to submit an Investigational New Drug (IND) application in early 2026.
Support Statement: Steve Mason, Co-COO of Altasciences, expressed pride in supporting Steel Therapeutics during this critical phase of their development journey.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Altasciences selezionata da Steel Therapeutics per supportare il lancio di uno studio tossicologico fondamentale su Fizurex™

About the author

Top News

Ford Announces $19.5B EV Restructuring Charges

Fed Cuts Interest Rates Amid Economic Concerns

SpaceX Targets $800 Billion Valuation in Secondary Sale

U.S. Consumer Sentiment Slightly Improves in December

Related Articles

Commvault Survey Reveals Rising Data Security Concerns Among New Yorkers

SEI Appoints Carl A. Guarino as Chairman, Initiating Leadership Transition

People Also Watch